Navigation Links
Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February
Date:1/20/2012

induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory B cell NHL without unacceptable rates of cardio toxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site,

http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of Pixuvri include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with Pixuvri in particular, including, without limitation, the potential failure of Pixuvri to prove safe and effective for the treatment of relapsed or refractory NHL and/or other tumors as determined by the FDA and/or the EMA, that CTI may not receive a positive opinion regarding the MAA from the CHMP in mid-February 2012 or at all, that the CHMP may reschedule timing of the issuance of its opinion on the MAA, that the CHMP may request additional information from CTI regarding Pixuvri, that CTI may not obtain a license to market Pixuvri in the E.U., that the EMA and/or the European Commission may not formally adopt the CHMP's opinion regarding Pixuvri, that the FDA may not complete the
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. UT-Battelle licenses tissue regeneration technologies to NellOne Therapeutics, Inc.
2. European mountain vegetation shows effects of warmer climate
3. DTU is participating in a European network on measurement of greenhouse gases
4. Register now for the European Congress on Osteoporosis & Osteoarthritis in Bordeaux
5. UK invests £75 million in European research infrastructure to support knowledge-based economy
6. EMBO awards Installation Grants to 7 European scientists
7. How does a plant survive with few mates or pollinators? A European herb has figured out its own way
8. New European project launched to address shortcomings in climate data
9. Misleading morphology: 3 European parasitoid wasp species are seasonal forms of just 1
10. Genomatix to partner in $41 million European epigenomics consortium
11. Pesticides pollute European waterbodies more than previously thought
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... Transparency Market Research has released ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... is forecast to reach US$ 2,671.8 Mn by 2022. ... systems by civil and government agencies. This is majorly ... activities across the globe that would elevate the demand ...
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... the Obesity Institute at Children,s National ... share ideas, failures and successes, and the future ... childhood obesity, both in the District of Columbia ... National seeks to reduce childhood obesity using a ...
... Virginia Tech Wake Forest University,s School of Biomedical Engineering ... Modeling and Simulation Award for 2008. The Office ... Director of the Army presented the award for research that ... associated with facial injury. The center was selected ...
... If you,re looking for bonefish from Miami down to ... from, and that is down slightly from the average ... who are counting, researchers speculate. The University of Miami,s ... sixth annual Florida Keys bonefish census, in conjunction with ...
Cached Biology News:Children's National convenes first childhood obesity symposium 2Children's National convenes first childhood obesity symposium 3Children's National convenes first childhood obesity symposium 4New dummy design and development wins US Department of Defense award 2Bonefish census reveals population holding steady 2
(Date:8/31/2015)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC ... announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd. ... an Investigational New Drug (IND) application for the topical ... completed a study in a rat model of dry ... efficacy and a more rapid onset of action than ...
(Date:8/31/2015)... and SHANGHAI , ... privately-held biopharmaceutical company developing next-generation antibiotics, today announced ... clinical study for its lead drug candidate MRX-I. ... treat drug-resistant bacteria such as MRSA and VRE, ... better tolerated therapeutic option than currently available oxazolidinone ...
(Date:8/31/2015)... Trimb Healthcare AB ("Trimb") today announced that it has ... a Dutch OTC company with operations in key European ... 16 million, with solid growth and leading brands in ... build a leading international OTC company, and this acquisition ... us a stronger North European OTC platform, from which ...
(Date:8/31/2015)... ... 2015 , ... There’s a new treatment option for excessive menstrual bleeding – ... FDA approved system in the last 14 years, and the only endometrial ablation product ... rate of 66%, the high Patient Satisfaction rate of 98%, and the fastest procedure ...
Breaking Biology Technology:Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... 2 The Foundation for,Biomedical Research (FBR) congratulates ... DeBakey the highest civilian honor it can bestow, ... to cardiovascular medicine,have improved the health of millions ... extraordinary talents as a surgeon, inventor, educator and,medical ...
... Roche Files CTA for Third Genmab Antibody,Summary: Genmab,s Partner Roche has ... ... Genmab Antibody, COPENHAGEN, October 2 Genmab ... Clinical Trial,Application (CTA) with the British Medicines and Healthcare products,Regulatory Agency ...
... N.J., Oct. 2 Synvista Therapeutics,Inc. (Amex: SYI ... Chief Executive Officer will present at the BIO InvestorForum,2007 ... BIO InvestorForum will,be held on October 9 - 11, ... Dr. Berkowitz will discuss the company,s planned and/or ...
Cached Biology Technology:Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal 2Genmab A/S - Company Announcement 2Synvista Therapeutics to Present at the BIO InvestorForum 2007 2Synvista Therapeutics to Present at the BIO InvestorForum 2007 3
BD BaculoGoldTM Transfection Kit 5 transfections...
... Purification Kit is designed for isolating DNA from ... protocol can be completed in less than one ... larger amounts of DNA. The purified DNA can ... Southern blotting. The MasterPure Kit was designed for ...
...
Sf9 Insect Cells (Frozen) in Max-XP Medium...
Biology Products: